Pharmiva AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 1.17 million compared to SEK 0.654 million a year ago. Revenue was SEK 1.17 million compared to SEK 0.654 million a year ago. Net loss was SEK 7.44 million compared to SEK 4.49 million a year ago. Basic loss per share from continuing operations was SEK 0.9 compared to SEK 0.63 a year ago.
For the six months, sales was SEK 1.6 million compared to SEK 1.31 million a year ago. Revenue was SEK 1.6 million compared to SEK 1.32 million a year ago. Net loss was SEK 13.64 million compared to SEK 10.28 million a year ago. Basic loss per share from continuing operations was SEK 1.77 compared to SEK 1.7 a year ago.